Is depersonalization disorder initiated by illicit drug use any different? A survey of 394 adults

Journal of Clinical Psychiatry

Volumn 70, Issue 10, 2009, Pages 1358-1364

  Simeon, Daphne ^a   Kozin, David S ^a   Segal, Karina ^a   Brenna, Lerch ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIS; PSYCHEDELIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEPERSONALIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE COURSE; DRUG ABUSE; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOTHERAPY; SCORING SYSTEM; STRUCTURED QUESTIONNAIRE; SUICIDE ATTEMPT; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; COMORBIDITY; DEPERSONALIZATION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; NUTRITION ASSESSMENT; PREVALENCE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 72849112713     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04370     Document Type: Article

References (39)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Hunter EC, Sierra M, David AS. The epidemiology of depersonalisation and derealisation: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2004;39(1):9-18. PubMed doi:10.1007/s00127-004-0701-4
3. Simeon D, Knutelska M, Nelson D, et al. Feeling unreal: a depersonalization disorder update of 117 cases. J Clin Psychiatry. 2003;64(9):990-997. PubMed
4. Baker D, Hunter E, Lawrence E, et al. Depersonalisation disorder: clinical features of 204 cases. Br J Psychiatry. 2003;182:428-433. PubMed doi:10.1192/bjp.182.5.428
5. Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res. 2000;93(2):153-164. PubMed doi:10.1016/S0165-1781(00)00100-1
6. Sierra M, Baker D, Medford N, et al. Unpacking the depersonalization syndrome: an exploratory factoranalysis on the Cambridge Depersonalization Scale. Psychol Med. 2005;35:1523-1532. PubMed doi:10.1017/S0033291705005325
7. Simeon D, Kozin DS, Segal K, et al. De-constructing depersonalization: further evidence for symptom clusters. Psychiatry Res. 2008;157(1-3):303-306. PubMed doi:10.1016/j.psychres.2007.07.007
8. Szymanski HV. Prolonged depersonalization after marijuana use. Am J Psychiatry. 1981;138:231-233. PubMed
9. Keshaven MS, Lishman WA. Prolonged depersonalization following cannabis abuse. Br J Addict. 1986;81(1):140-142. PubMed doi:10.1111/j.1360-0443.1986. tb00306.x
10. Medford N, Baker D, Hunter E, et al. Chronic depersonalisation following illicit drug use: a controlled analysis of 40 cases. Addiction. 2003;98:1731-1736. PubMed doi:10.1111/j.1360-0443.2003.00548.x
11. van Ijzendoorn MH, Schuengel C. The measurement of dissociation in normal and clinical populations: meta-analytic validation of the Dissociative Experiences Scale (DES). Clin Psychol Rev. 1996;16(5):365-382. doi:10.1016/0272-7358(96)00006-2 (Pubitemid 26296162)
12. Simeon D, Guralnik O, Hazlett EA, et al. Feeling unreal: a PET study of depersonalization disorder. Am J Psychiatry. 2000;157:1782-1788. PubMed doi:10.1176/appi.ajp.157.11.1782
13. Simeon D, Knutelska M, Yehuda R, et al. Hypothalamic-pituitary-adrenal axis function in dissociative disorders, posttraumatic stress disorder, and healthy volunteers. Biol Psychiatry. 2007;61:966-973. PubMed doi:10.1016/j.biopsych.2006.07.030 (Pubitemid 46482460)
14. Simeon D, Guralnik O, Knutelska M, et al. Basal norepinephrine in depersonalization disorder. Psychiatry Res. 2003;121(1):93-97. PubMed doi:10.1016/S0165-1781(03)00205-1
15. Phillips ML, Medford N, Senior C, et al. Depersonalization disorder: thinking without feeling. Psychiatry Res. 2001;108(3):145-160. PubMed doi:10.1016/S0925-4927(01)00119-6 (Pubitemid 34072915)
16. Lemche E, Surguladze SA, Giampietro VP, et al. Limbic and prefrontal responses to facial emotion expressions in depersonalization. Neuroreport. 2007;18:473-477. PubMed doi:10.1097/WNR.0b013e328057deb3 (Pubitemid 46668037)
17. Lanius RA, Williamson PC, Boksman K, et al. Brain activation during script-driven imagery induced dissociative responses in PTSD: a functional magnetic resonance imaging investigation. Biol Psychiatry. 2002;52:305-311. PubMed doi:10.1016/S0006-3223(02)01367-7 (Pubitemid 35245969)
18. Reinders AA, Nijenhuis ER, Quak J, et al. Psychobiological characteristics of dissociative identity disorder: a symptom provocation study. Biol Psychiatry. 2006;60:730-740. PubMed doi:10.1016/j.biopsych.2005.12.019 (Pubitemid 44427763)
19. Guy W. Assessment Manual for Psychopharmacology. Washington, DC: US Dept of HEW Publications; 1976.
20. Sheehan DV. The Anxiety Disease. New York, NY: Scribner; 1983.
21. Simeon D, Guralnik O, Schmeidler J, et al. Fluoxetine therapy in depersonalization disorder: randomised controlled trial. Br J Psychiatry. 2004;185:31-36. PubMed doi:10.1192/bjp.185.1.31 (Pubitemid 38951627)
22. Sierra M, Phillips ML, Krystal J, et al. A placebo-controlled, crossover trial of lamotrigine in depersonalization disorder. J Psychopharmacol. 2003;17:103-105. PubMed doi:10.1177/0269881103017001712 (Pubitemid 36373147)
23. Simeon D, Knutelska M. An open trial of naltrexone in the treatment of depersonalization disorder. J Clin Psychopharmacol. 2005;25:267-270. PubMed doi:10.1097/01.jcp.0000162803.61700.4f (Pubitemid 40685793)
24. Hunter ECM, Phillips ML, Chalder T, et al. Depersonalisation disorder: a cognitive-behavioural conceptualization. Behav Res Ther. 2003;41:1451-1467. PubMed doi:10.1016/S0005-7967(03)00066-4
25. Hunter EC, Baker D, Phillips ML, et al. Cognitive-behaviour therapy for depersonalisation disorder: an open study. Behav Res Ther. 2005;43:1121-1130. PubMed doi:10.1016/j.brat.2004.08.003 (Pubitemid 40984737)
26. Simeon D, Giesbrecht T, Knutelska M, et al. Alexithymia, cognitive failures, and absorption in depersonalization disorder. J Nerv Ment Dis. In press.
27. Bernstein-Carlson E, Putnam FW. An update on the Dissociative Experiences Scale. Dissociation. 1993;6:16-27.
28. Simeon D, Knutelska M, Nelson D, et al. Examination of the pathological dissociation taxon in depersonalization disorder. J Nerv Ment Dis. 2003;191:738-744. PubMed doi:10.1097/01.nmd.0000095126.21206.3e (Pubitemid 37464502)
29. Simeon D. Depersonalization disorder: a contemporary overview. CNS Drugs. 2004;18:343-354. PubMed doi:10.2165/00023210-200418060-00002
30. Mathew RJ, Wilson WH, Chiu NY, et al. Regional cerebral blood flow and depersonalization after tetrahydrocannabinol administration. Acta Psychiatr Scand. 1999;100:67-75. PubMed doi:10.1111/j.1600-0447.1999.tb10916.x
31. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005;57(6):594-608. PubMed doi:10.1016/j.biopsych.2004.12.006 (Pubitemid 40409699)
32. Feigenbaum JJ, Bergmann F, Richmond SA, et al. Nonpsychotropic cannabinoid acts as a functional N-methyld- aspartate receptor blocker. Proc Natl Acad Sci U S A. 1989;86:9584-9587. PubMed doi:10.1073/pnas.86.23.9584 (Pubitemid 20010472)
33. Simeon D, Hollander E, Stein DJ, et al. Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Res. 1995;58(2):161-164. PubMed doi:10.1016/0165-1781(95)02538-8
34. Southwick SM, Krystal JH, Bremner JD, et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 1997;54:749-758. PubMed
35. D'Souza DC, Gil RB, Zuzarte E, et al. Gamma-aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry. 2006;59(2):128-137. PubMed doi:10.1016/j. biopsych.2005.06.020
36. Anand A, Charney D, Oren D, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Arch Gen Psychiatry. 2000;57:270-276. PubMed doi:10.1001/archpsyc.57.3.270
37. Deakin JF, Lees J, McKie S, et al. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry. 2008;65(2):154-164. PubMed doi:10.1001/archgenpsychiatry. 2007.37
38. Walsh SL, Geter-Douglas B, Strain EC, et al. Enadoline and butorphanol: evaluation of kappa agonists on cocaine pharmacodynamics and cocaine self-administration in humans. J Pharmacol Exp Ther. 2001;299:147-158. PubMed
39. Simeon D, Guralnik O, Schmeidler J, et al. The role of childhood interpersonal trauma in depersonalization disorder. Am J Psychiatry. 2001;158:1027-1033. PubMed doi:10.1176/appi.ajp.158.7.1027 (Pubitemid 32623105)